Prognostic Indexes for Alcoholic Hepatitis


  • Gabriela P. Coral UFCSPA
  • Cristiane V. Tovo Universidade Federal de Ciências da Saúde de Porto Alegre (UFCSPA)
  • Mariana de A. Pranke UFCSPA
  • Angelo A. de Mattos UFCSPA



alcoholic hepatitis, prognostic indexes, liver biopsy, steatosis, alcoholism


Alcohol abuse is the major source of liver disease. The prevalence of alcoholic hepatitis (AH) is unknown, but histologic studies demonstrated that AH may be present in approximately 10% to 35% of hospitalized patients with alcoholism. The assessment of severity permits the identification of patients that will improve without medical therapy and those that will have a high mortality if not treated. A variety of scoring systems has been used to quantity the severity of AH and guides its treatment.

The scores more commonly used are: Maddrey’s discriminant function (DF), Model for End-Stage Liver Disease (MELD), Glasgow Alcoholic Hepatitis Score (GAHS) and Age, serum Bilirubin, INR (International Normalized Ratio), and serum Creatinine (ABIC). Some others prognostic indexes assess the efficacy of treatment, like Lille score, and Early Change in Bilirubin Levels. Histologic findings are showed to predict additional findings like risk of infection and poor prognosis even in a subgroup considered of better prognosis.

The authors strongly recommend liver biopsy to confirm the diagnosis of AH and to discriminate patients with risk of infection and death without medical therapy. In our point of view, this method has been showed to be the best prognostic markers for AH in nowadays. In conclusion, AH is a severe complication among heavy drinkers and frequently results in poor short term prognosis. Various clinical scores are useful to differentiate patients with high mortality if not treated and are similar in predicting the outcome. More recently, the liver biopsy and a histologic score including fibrosis, megamitochondria, neutrophil infiltration and bilirubinostasis showed promising results and should be recommended.


Lim SS, Vos T, Flaxman AD, Danaei G, Shibuya K, Amman M, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380:2224–2260.

O’Shea RS, Dasarathy S, McCullough AJ. Practice Guideline Committee of the American Association for the Study of Liver Diseases; Practice Parameters Committee of the American College of Gastroenterology. Alcoholic liver disease. Hepatology 2010;51:307-328.

WHO. WHO Global status report on alcohol, [online], (2011).

Rehm J, Samokhvalov AV, Shield KD. Global Burden of alcoholic liver diseases. J Hepatol 2013;59:160-168.

Gawryszewski VP, Monteiro MG. Mortality from diseases, conditions and injuries where alcohol is a necessary cause in the Americas, 2007-09. Addiction 2014;109:570-7.

Nader LA, Mattos AA, Bastos GAN. Burden of liver disease in Brazil. Liver Int 2014;34:844–849.

Crabb DW. Pathogenesis of alcoholic liver disease: newer mechanisms of injury. Keio J Med 1999;48:184-188.

Teli MR, Day CP, Burt AD, Bennett MK, James OF. Determinants of progression to cirrhosis or fibrosis in pure alcoholic fatty liver. Lancet 1995;346: 987-990.

Orrego H, Blake JE, Blendis LM, Medline A. Prognosis of alcoholic cirrhosis in the presence and absence of alcoholic hepatitis. Gastroenterology 1987;92: 208-214.

Lucey MR, Mathurin P, Morgan TR. Alcoholic hepatitis. N Engl J Med 2009;360: 2758-2769.

Trabut JB, Plat A, Thepot V, Fontaine H, Vallet-Pichard A, et al. Influence of liver biopsy on abstinence in alcohol-dependent patients. Alcohol 2008;43:559-563.

Moreau R, Jalan R, Gines P, Pavesi M, Angeli P, Cordoba J, et al. CANONIC Study Investigators of the EASL–CLIF Consortium. Acute-on-Chronic Liver Failure Is a Distinct Syndrome That Develops in Patients With Acute Decompensation of Cirrhosis. Gastroenterology 2013;144:1426–1437.

Jaurigue MM, Cappell MS. Therapy for alcoholic liver disease. World J Gastroenterol 2014;20:2143-2158.

European Association for the Study of Liver. EASL clinical practical guidelines: management of alcoholic liver disease. J Hepatol 2012;57:399-420.

Mathurin P, Mendenhall CL, Carithers RL, Ramond MJ, Maddrey WC, Garstide P, et al.Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis (AH): individual data analysis of the last three randomized placebo controlled double blind trials of corticosteroids in severe AH. J Hepatol 2002;36:480-487.

Mathurin P, O’Grady J, Carithers RL, Phillips M, Louvet A, Mendenhall CL, et al. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis: meta-analysis of individual patient data. Gut 2011;60:255-260.

Imperiale TF, McCullough AJ. Do corticosteroids reduce mortality from alcoholic hepatitis? A meta-analysis of the randomized trials. Ann Intern Med 1990;113:299-307.

Rambaldi A, Saconato HH, Christensen E, Thorlund K, Wetterslev J, Gluud C. Systematic review: glucocorticosteroids for alcoholic hepatitis--a Cochrane Hepato-Biliary Group systematic review with meta-analyses and trial sequential analyses of randomized clinical trials. Aliment Pharmacol Ther 2008;27:1167-1178.

Sidhu SS, Goyal O, Singla P, Gupta D, Sood A, Chhina RS, et al. Corticosteroid plus pentoxifylline is not better than corticosteroid alone for improving survival in severe alcoholic hepatitis (COPE trial). Dig Dis Sci 2012;57:1664-1671.

Mathurin P, Louvet A, Duhamel A, Nahon P, Carbonell N, Boursier J, et al. Prednisolone with vs without pentoxifylline and survival of patients with severe alcoholic hepatitis: a randomized clinical trial. JAMA 2013;310:1033-1041.

Lebrec D, Thabut D, Oberti F, Perarnau JM, Condat B, Barraud H, et al. Pentoxifylline does not decrease short term mortality but does reduce complications in patients with advanced cirrhosis. Gastroenterology 2010;138:1755-1762.

Thursz MR, Richardson P, Allison ME, Austin A, Bowers M. Steroids or Pentoxifylline for Alcoholic Hepatitis: Results of the STOPAH Trial. Late-Breaking Abstracts. Hepatology 2014;60:1267A.

Higuera-de la Tijera F, Servín-Caamaño AI, Cruz-Herrera J, Serralde-Zúñiga AE, Abdo-Francis JM, Gutiérrez-Reyes G, et al . Treatment with metadoxine and its impact on early mortality in patients with severe alcoholic hepatitis. Ann Hepatol 2014;13:343-52.

Stickel F, Seitz HK. Update on the Management of Alcoholic Steatohepatitis. J Gastrointestin Liver Dis 2013;22:189-197.

Carithers RL, Herlong HF, Diehl AM, Shaw EW, Combes B, Fallon HJ, et al. Methylprednisolone therapy in patients with severe alcoholic hepatitis. A randomized multicenter trial. Ann Intern Med 1989;110:685-690.

Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001;33:464–470.

Sheth M, Riggs M, Patel T. Utility of the Mayo End-Stage Liver Disease (MELD) score in assessing prognosis of patients with alcoholic hepatitis. BMC Gastroenterol 2002;2:2.

Dunn W, Jamil LH, Brown LS, Wiesner RH, Kim WR, Menon KV, et al. MELD accurately predicts mortality in patients with alcoholic hepatitis. Hepatology 2005;41:353-358.

Srikureja W, Kyulo NL, Runyon BA, Hu KQ. MELD score is a better prognostic model than Child-Turcotte-Pugh score or Discriminant Function score in patients with alcoholic hepatitis. J Hepatol 2005;42:700-706.

Forrest EH, Evans CD, Stewart S, Phillips M, Oo YH, McAvoy NC. et al. Analysis of factors related to mortality in alcoholic hepatitis and the derivation and validation of the Glasgow alcoholic hepatitis score. Gut 2005;54:1174–9.

Forrest EH, Morris AJ, Stewart S, Phillips M, Oo YH, Fisher NC, et al. The Glasgow alcoholic hepatitis score identifies patients who may benefit from corticosteroids. Gut 2007;56:1743–1746.

Dominguez M, Rincón D, Abraldes JG, Miquel R, Colmenero J, Bellot P, et al. A New scoring system for prognostic stratification of patients with alcoholic hepatitis. Am J Gastroenterol 2008;103:2747-56.

Louvet A, Naveau S, Abdelnour M, Ramond MJ, Diaz E, Dharancy S, et al. The Lille model: a new tool for thepapeutic strategy in patients with severe alcoholic hepatitis treated with steroids. Hepatology 2007;45:1348-54.

Mathurin P, Abdelnour M, Ramond MJ, Carbonell N, Fartoux L, Serfaty L, et al. Early change in bilirubin levels is an important prognostic factor in severe alcoholic hepatitis treated with prednisolone. Hepatology 2003;38:1363–9.

Maddrey WC, Boitnott JK, Bedine MS, Weber FL Jr, Mezey E, White RI Jr. Corticosteroid therapy of alcoholic hepatitis. Gastroenterology 1978;75:193-199.

Vaa BE, Asrani SK, Dunn W, Kamath PS, Shah VH. Influence of Serum Sodium on MELD-Based Survival Prediction in Alcoholic Hepatitis. Mayo Clin Proc 2011;86:37-42.

Morris JM, Forrest EH. Bilirubin response to corticosteroids in severe alcoholic hepatitis. Eur J Gastroenterol Hepatol 2005;17:759–62.

Sandahl TD, Jepsen P, Ott P, Vilstrup H. Validation of prognostic scores for clinical use in patients with alcoholic hepatitis. Scand J Gastroenterol 2011;46:1127–32.

Palaniyappan N, Subramanian V, Ramappa V, Ryder SD, Kaye P, Aithal GP. The Utility of Scoring Systems in Predicting Early and Late Mortality in Alcoholic Hepatitis: Whose Score Is It Anyway? International J Hepatol 2012;2012: 624675.

Lafferty H, Stanley AJ, Forrest EH. The management of alcoholic hepatitis: a prospective comparison of scoring systems. Aliment Pharmacol Ther 2013;38:603–10.

Papastergiou V, Tsochatzis EA, Pieri G, Thalassinos E, Dhar A, Bruno S, et al. Nine scoring models for short-term mortality in alcoholic hepatitis: cross-validation in a biopsy-proven cohort. Aliment Pharmacol Ther 2014;39:721-32.

Cuthbert JA, Arslanlar S, Yepuri J, Montrose M, Ahn CW. Predicting short-term mortality and long-term survival for hospitalized US patients with alcoholic hepatitis. Dig Dis Sci 2014;597:1594-602.

Lee M, Kim W, Choi Y, Kim S, Kim D, Yu SJ, et al. Spontaneous evolution in bilirubin levels predicts liver-related mortality in patients with alcoholic hepatitis. PLoS One 2014;9:e100870.

Hall PD. Pathological spectrum of alcoholic liver disease. Alcohol Alcohol Suppl 1994;2:303-313.

Lefkowitch JH. Morphology of alcoholic liver disease. Clin Liver Dis 2005;9:37-53.

Mathurin P, Beuzin F, Louvet A, Carrié-Ganne N, Balian A, Trinchet JC, et al. Fibrosis progression occurs in a subgroup of heavy drinkers with typical histological features. Aliment Pharmacol Ther 2007;25:1047-1054.

Spahr L, Rubbia-Brandt L, Genevay M, Hadengue A, Giostra E. Early liver biopsy, intraparenchymal cholestasis, and prognosis in patients with alcoholic steatohepatitis. BMC Gastroenterol 2011;11:115.

Altamirano J, Miquel R, Katoonizadeh A, Abraldes JG, Duarte-Rojo A, Louvet A, et al. A Histologic Scoring System for Prognosis of Patients With Alcoholic Hepatitis. Gastroenterology 2014;146:1231–1239.

Kasztelan-Szczerbinska B, Slomka M, Celinski K, Szczerbinski M. Alkaline phosphatase: the next independent predictor of the poor 90-day outcome in alcoholic hepatitis. Biomed Res Int 2013;2013:614081.

Rincon D, Lo Iacono O, Ripoll C, Gomez-Camarero J, Salcedo M, et al (2007) Prognostic value of hepatic venous pressure gradient for in-hospital mortality of patients with severe acute alcoholic hepatitis. Aliment Pharmacol Ther 25:841-8.

Altamirano J, Fagundes C, Dominguez M, García E, Michelena J, et al (2012) Acute kidney injury is an early predictor of mortality for patients with alcoholic hepatitis. Clin Gastroenterol Hepatol 10:65-71.

Trépo E, Ouziel R, Pradat P, Momozawa Y, Quertinmont E, Gustot T, et al. Marked 25-hydroxyvitamin D deficiency is associated with poor prognosis in patients with alcoholic liver disease. J Hepatol 2013;59:344–350.